Clinical trial
Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen…
NCT00036270 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00036270 |
|---|---|
| Title | Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane |
| Official title | Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen For 2.5- 3 Years Followed By Exemestane (Aromasin) For A Total Of 5 Years As Adjuvant Therapy For Postmenopausal, Receptor Positive, Node Negative or Node Positive Breast Cancer Patients |
| Acronym | TEAM |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | exemestane (Aromasin), tamoxifen + exemestane |
| Enrollment | 9,779 |
| Start date | Aug 1, 2001 |
| Primary completion | Oct 1, 2008 |
| Completion | Feb 1, 2011 |
| First posted | May 9, 2002 |
| Last update posted | Oct 28, 2015 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: